Aliases & Classifications for Peritoneum Cancer

MalaCards integrated aliases for Peritoneum Cancer:

Name: Peritoneum Cancer 12 15
Peritoneal Neoplasm 12 17
Malignant Tumor of Peritoneum 70
Cancer of Peritoneum 12
Peritoneal Neoplasms 70

Classifications:



External Ids:

Disease Ontology 12 DOID:1725
ICD9CM 34 158.8
SNOMED-CT 67 187808008
ICD10 32 C48.1 C48.2
UMLS 70 C0031149 C0153466 C0153467

Summaries for Peritoneum Cancer

Disease Ontology : 12 An organ system cancer that is located in the peritoneum.

MalaCards based summary : Peritoneum Cancer, also known as peritoneal neoplasm, is related to peritoneal mesothelioma and fallopian tube clear cell adenocarcinoma, and has symptoms including sister mary joseph's nodule An important gene associated with Peritoneum Cancer is CALB2 (Calbindin 2), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Trabectedin and lanreotide have been mentioned in the context of this disorder. Affiliated tissues include ovary, colon and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Peritoneum Cancer

Diseases related to Peritoneum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 479)
# Related Disease Score Top Affiliating Genes
1 peritoneal mesothelioma 30.9 WT1 NF2 EGFR CEACAM5 CDKN2A CALB2
2 fallopian tube clear cell adenocarcinoma 10.5 BRCA2 BRCA1
3 ovary transitional cell carcinoma 10.5 BRCA2 BRCA1
4 fallopian tube adenocarcinoma 10.4 CALB2 BRCA1
5 cancerophobia 10.4 BRCA2 BRCA1
6 clear cell cystadenofibroma 10.4 TP53 CALB2
7 nosophobia 10.4 BRCA2 BRCA1
8 rete testis adenoma 10.4 PAX8 CALB2
9 tetraploidy 10.4 BRCA2 BRCA1
10 pax6-related aniridia 10.4 WT1 BRCA2
11 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 10.4 BRCA2 BRCA1
12 spindle cell thymoma 10.4 KRT5 CALB2
13 spermatic cord cancer 10.4 WT1 KRT5
14 ruvalcaba syndrome 10.4 BRCA2 BRCA1
15 ureter squamous cell carcinoma 10.4 KRT7 KRT5
16 fallopian tube squamous cell carcinoma 10.4 WT1 CDKN2A
17 peritoneal serous papillary adenocarcinoma 10.4 WT1 PTGER4
18 nevus of ota 10.4 TP53 BAP1
19 bartholin's gland disease 10.4 KRT7 CALB2
20 epithelial predominant wilms' tumor 10.4 WT1 KRT7
21 thymus basaloid carcinoma 10.4 PAX8 KRT5
22 bap1 tumor predisposition syndrome 10.4 BRCA2 BAP1
23 ceruminoma 10.4 KRT7 KRT5
24 penile urethral cancer 10.4 KRT5 CDKN2A
25 sarcomatoid basal cell carcinoma 10.4 PTGER4 KRT5
26 testicular fibroma 10.4 WT1 KRT5 CALB2
27 heart cancer 10.4 MIR1266 KRT5 CALB2
28 nephrogenic adenofibroma 10.4 WT1 KRT7
29 subareolar duct papillomatosis 10.4 KRT7 KRT5
30 liver fibroma 10.4 MSLN KRT5 CALB2
31 nipple benign neoplasm 10.4 KRT7 KRT5
32 auditory system benign neoplasm 10.4 KRT7 KRT5
33 male urethral cancer 10.4 KRT5 CDKN2A
34 asbestosis 10.4 WT1 MSLN CALB2
35 ceruminous adenocarcinoma 10.4 KRT7 KRT5
36 bladder benign neoplasm 10.4 PAX8 KRT7
37 fallopian tube carcinosarcoma 10.4 WT1 TP53 CALB2
38 nephrogenic adenoma of urinary bladder 10.4 PAX8 KRT7
39 wolffian duct adenoma 10.4 PAX8 KRT7
40 cervical basaloid squamous cell carcinoma 10.3 KRT7 CDKN2A
41 epididymal neoplasm 10.3 WT1 KRT7 CALB2
42 cervical serous adenocarcinoma 10.3 WT1 CEACAM5
43 bartholin's gland carcinoma 10.3 PAX8 KRT7
44 ovarian sex-cord stromal tumor 10.3 WT1 KRT7 CALB2
45 anus basaloid carcinoma 10.3 PTGER4 KRT7
46 lung clear cell carcinoma 10.3 KRT7 KRT5
47 endometrial serous adenocarcinoma 10.3 WT1 TP53 BRCA1
48 mutagen sensitivity 10.3 TP53 BRCA2 BRCA1
49 vulvar intraepithelial neoplasia 10.3 TP53 CDKN2A
50 laryngeal small cell carcinoma 10.3 KRT5 CDKN2A

Comorbidity relations with Peritoneum Cancer via Phenotypic Disease Network (PDN):


Ovarian Cancer

Graphical network of the top 20 diseases related to Peritoneum Cancer:



Diseases related to Peritoneum Cancer

Symptoms & Phenotypes for Peritoneum Cancer

UMLS symptoms related to Peritoneum Cancer:


sister mary joseph's nodule

GenomeRNAi Phenotypes related to Peritoneum Cancer according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.02 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.02 EGFR
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.02 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.02 BRCA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.02 BRCA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.02 WT1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.02 WT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.02 PAX8
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.02 BRCA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.02 BRCA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.02 EGFR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.02 BRCA1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.02 EGFR WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.02 WT1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.02 EGFR WT1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.02 WT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.02 H2AC18
18 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.02 EGFR WT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.02 EGFR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.02 H2AC18
21 Synthetic lethal with cisplatin GR00101-A-1 8.8 BRCA1 BRCA2 NF2

MGI Mouse Phenotypes related to Peritoneum Cancer:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 BAP1 BRCA1 BRCA2 CDKN2A EGFR EPCAM
2 growth/size/body region MP:0005378 10.3 BAP1 BRCA1 BRCA2 CDKN2A EGFR EPCAM
3 embryo MP:0005380 10.27 BAP1 BRCA1 BRCA2 CDKN2A EGFR EPCAM
4 endocrine/exocrine gland MP:0005379 10.22 BAP1 BRCA1 BRCA2 CDKN2A EGFR EPCAM
5 mortality/aging MP:0010768 10.21 BAP1 BRCA1 BRCA2 CDKN2A EGFR EPCAM
6 digestive/alimentary MP:0005381 10.11 BAP1 BRCA1 BRCA2 CDKN2A EGFR EPCAM
7 integument MP:0010771 10.09 BAP1 BRCA1 BRCA2 CDKN2A EGFR KRT5
8 neoplasm MP:0002006 9.97 BAP1 BRCA1 BRCA2 CDKN2A EGFR NF2
9 limbs/digits/tail MP:0005371 9.95 BRCA1 BRCA2 EGFR KRT5 PAX8 RAD51D
10 normal MP:0002873 9.81 BRCA1 BRCA2 CALB2 EGFR MSLN PAX8
11 no phenotypic analysis MP:0003012 9.8 BAP1 CDKN2A EGFR EPCAM PAX8 TP53
12 reproductive system MP:0005389 9.65 BAP1 BRCA1 BRCA2 CDKN2A EGFR NF2
13 respiratory system MP:0005388 9.23 BAP1 BRCA1 CDKN2A EGFR NF2 PTGER4

Drugs & Therapeutics for Peritoneum Cancer

Drugs for Peritoneum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 267)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
2
lanreotide Approved Phase 3 108736-35-2
3
Nintedanib Approved Phase 3 656247-17-5 56843413
4
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
5
Irinotecan Approved, Investigational Phase 2, Phase 3 100286-90-6, 97682-44-5 60838
6
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
7
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
8
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
9
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
10
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
11
Ifosfamide Approved Phase 3 3778-73-2 3690
12
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
13
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
14
Epirubicin Approved Phase 3 56420-45-2 41867
15
Raltitrexed Approved, Investigational Phase 3 112887-68-0 104758
16
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
17
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
18
Trebananib Investigational Phase 3 894356-79-7
19
Oregovomab Investigational Phase 3 213327-37-8
20
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
21 Trace Elements Phase 3
22 Micronutrients Phase 3
23 Carotenoids Phase 3
24 Epothilones Phase 3
25 Epothilone B Phase 3
26 Angiopeptin Phase 3
27 Hormones Phase 3
28 Hormone Antagonists Phase 3
29 Estrogens Phase 3
30 Estrogen Receptor Antagonists Phase 3
31 Estrogen Antagonists Phase 3
32 Calcium, Dietary Phase 3
33 Aromatase Inhibitors Phase 3
34 Mitomycins Phase 3
35 Alkylating Agents Phase 3
36 taxane Phase 3
37
Isophosphamide mustard Phase 3 100427
38 Dialysis Solutions Phase 3
39
Calcium Nutraceutical Phase 3 7440-70-2 271
40
Gemcitabine Approved Phase 2 95058-81-4 60750
41
Sodium citrate Approved, Investigational Phase 2 68-04-2
42
Tamoxifen Approved Phase 2 10540-29-1 2733526
43
Sulfamethazine Approved, Investigational, Vet_approved Phase 2 57-68-1 5327
44
Fluorouracil Approved Phase 2 51-21-8 3385
45
leucovorin Approved Phase 2 58-05-9 6006
46
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
47
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
48
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
49
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
50
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0

Interventional clinical trials:

(show top 50) (show all 323)
# Name Status NCT ID Phase Drugs
1 An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice Recruiting NCT01932125 Phase 4 Bevacizumab
2 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
3 Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis Unknown status NCT02840331 Phase 3 St. John's Wort
4 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
5 Concentration-based Versus Body Surface Area-based Peroperative Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis' Treatment - Randomized Non-blinded Phase III Clinical Trial Unknown status NCT03028155 Phase 3 Oxaliplatin: BSA-based HIPEC;Oxaliplatin: Concentration-based HIPEC
6 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
7 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
8 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
9 Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
10 A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
11 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
12 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
13 A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
14 A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma Completed NCT00052962 Phase 3
15 A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT01846611 Phase 3 Trabectedin;DOXIL;Dexamethasone;DOXIL
16 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
17 The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
18 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
19 Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients. Completed NCT00216372 Phase 3 Lanreotide (microparticle formulation)
20 A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. Completed NCT01524094 Phase 3 Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)
21 Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Completed NCT01015118 Phase 3 Placebo;Paclitaxel;BIBF 1120;Carboplatin;Paclitaxel;Carboplatin
22 Phase III Study Evaluating the Use of Systemic Chemotherapy and Chemohyperthemia Intraperitoneal Preoperatively (CHIP) and After Maximum Resection of Peritoneal Carcinomatosis Originating With Colorectal Cancer Completed NCT00769405 Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
23 Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study Recruiting NCT02758951 Phase 2, Phase 3
24 A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036) Recruiting NCT03740165 Phase 3 Placebo for pembrolizumab;Carboplatin;Paclitaxel;Olaparib;Placebo for olaparib;Docetaxel
25 Multi-center, Randomized Controlled, Phase III Trials to Evaluate the Safety and Effectiveness After Cycles Reduction of Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer Recruiting NCT03693248 Phase 3 Two cycles of neoadjuvant chemotherapy
26 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
27 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
28 A Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy After Colectomy in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis Recruiting NCT04370925 Phase 3 Systemic chemotherapy
29 A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Recruiting NCT04498117 Phase 3 Paclitaxel;Carboplatin
30 Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Recruiting NCT03348150 Phase 3 Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
31 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study). Recruiting NCT04111978 Phase 3 Letrozole 2.5mg
32 A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01462890 Phase 3 Paclitaxel;Carboplatin
33 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
34 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
35 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
36 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT03635489 Phase 3 Paclitaxel;Bevacizumab;Carboplatin;Placebo
37 A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
38 Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Colon Cancer at High Risk of Peritoneal Carcinomatosis Active, not recruiting NCT02231086 Phase 3 Standard adjuvant systemic chemotherapy
39 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
40 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
41 Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction Active, not recruiting NCT02158988 Phase 3
42 A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Systemic Chemotherapy And Cytoreductive Surgery (CRS) in the Treatment of Peritoneal Carcinomatosis From Gastric Cancer Not yet recruiting NCT03179579 Phase 3
43 Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer Terminated NCT01683864 Phase 2, Phase 3 positive cytology with HIPEC
44 A Randomized Phase III Trial in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer With a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821 Withdrawn NCT00693342 Phase 3
45 Use of Changes in CA 125 Doubling Time to Detect Activity of Cytostatic Agents in Women Relapsing With Ovarian Carcinoma. Study 1-Tamoxifen Unknown status NCT00305838 Phase 2 tamoxifen citrate
46 Randomized Phase II AGO-Study Comparing Combined Liposomal Doxorubicin (Myocet) and Gemcitabine (Gemzar) With Liposomal Doxorubicin (Myocet) Monotherapy in Platinum-Refractory and Platinum-Resistant Epithelial Cancer of the Ovary, Fallopian Tube and the Peritoneum Unknown status NCT01100372 Phase 2 gemcitabine hydrochloride;liposome-encapsulated doxorubicin citrate
47 Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial Unknown status NCT00454519 Phase 2
48 A Phase II Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Unknown status NCT01570582 Phase 2 carboplatin and paclitaxel
49 Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer Unknown status NCT01575730 Phase 2 Hyperthermic intraoperative Peritoneal Chemoperfusion
50 Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol - The PIPAC-OPC2 Trial Unknown status NCT03287375 Phase 2 PIPAC

Search NIH Clinical Center for Peritoneum Cancer

Genetic Tests for Peritoneum Cancer

Anatomical Context for Peritoneum Cancer

MalaCards organs/tissues related to Peritoneum Cancer:

40
Ovary, Colon, T Cells, Pancreas, Endothelial, Liver, Uterus

Publications for Peritoneum Cancer

Articles related to Peritoneum Cancer:

(show all 29)
# Title Authors PMID Year
1
Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 61
33688945 2021
2
Osteopontin, GLUT1 and Ki67 expression in malignant peritoneal mesothelioma: Prognostic implications. 61
32510678 2020
3
Metachronous occurrence of two different histological subtypes of endometriosis-related neoplasms. 61
30603661 2019
4
[Perioperative care of epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. 61
30686730 2019
5
Changes in the Management and Prognosis of Ovarian Cancer Due to the New FIGO and WHO Classifications: A Case Series Observational Descriptive Study. Seven Years of Follow-up. 61
30045138 2018
6
Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. 61
29206890 2018
7
FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei. 61
26907364 2016
8
Progression of peritoneal adenomucinosis to the scrotum: a rare occurrence treated with cytoreductive surgery and hyperthermic chemoperfusion of the scrotum in two patients. 61
25100893 2014
9
Epidemiology of cancers in Serbia and possible connection with cyanobacterial blooms. 61
25436472 2014
10
From bacteria to antineoplastic: epothilones a successful history. 61
23343081 2013
11
Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. 61
21874229 2011
12
Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. 61
21543188 2011
13
Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. 61
20414103 2010
14
Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. 61
19361840 2009
15
The diagnostic problems in patient with ascites, elevated Ca 125 level and autoantibodies against nuclear antigens and smooth muscle antigens mimicking advanced ovarian carcinoma--case study. 61
18624115 2008
16
Cancer risk after cessation of asbestos exposure: a cohort study of Italian asbestos cement workers. 61
17704197 2008
17
[Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part II: evaluation of stomatognathic system in BRCA1 gene mutation carriers after prophylactic adnexectomy]. 61
19374245 2008
18
[Clinical and morphological characteristics of gastrointestinal stromal tumors]. 61
18074824 2007
19
Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry. 61
17425204 2007
20
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. 61
16260202 2005
21
Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. 61
15894368 2005
22
Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. 61
12664303 2003
23
[Mortality in a cohort of asbestos cement workers in Bari]. 61
12125387 2002
24
[Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study]. 61
11535965 2001
25
The hazards of chrysotile asbestos: a critical review. 61
10441898 1999
26
Cancer mortality among pulp and paper workers in Poland. A cohort study. 61
9187043 1997
27
[Recurrent ascites in peritoneal mesothelioma. Its diagnostic and therapeutic management]. 61
7742058 1995
28
The laparoscopic features of certain peritoneal neoplasm. 61
14492250 1962
29
[Considerations on a case of primary peritoneal neoplasm subjected to local treatment with radiophosphorus]. 61
13805415 1959

Variations for Peritoneum Cancer

Expression for Peritoneum Cancer

Search GEO for disease gene expression data for Peritoneum Cancer.

Pathways for Peritoneum Cancer

Pathways related to Peritoneum Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.52 TP53 EGFR CDKN2A BRCA2 BRCA1
2
Show member pathways
12.4 TP53 EGFR CDKN2A BRCA2 BRCA1
3 12.16 TP53 PTGER4 PAX8 EGFR CDKN2A BRCA2
4 12.04 NF2 KRT7 KRT5 EPCAM BAP1
5
Show member pathways
12.03 RAD51D RAD51C BRCA2 BRCA1
6 11.81 TP53 EGFR BRCA2 BRCA1
7
Show member pathways
11.73 RAD51D RAD51C BRCA2 BRCA1
8
Show member pathways
11.61 TP53 BRCA2 BRCA1
9 11.53 TP53 CDKN2A BRCA1
10 11.52 TP53 EGFR CDKN2A
11 11.25 TP53 EGFR CDKN2A
12 10.97 TP53 NF2 EGFR CDKN2A

GO Terms for Peritoneum Cancer

Cellular components related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.03 WT1 TP53 RAD51D RAD51C PAX8 NF2
2 Rad51B-Rad51C-Rad51D-XRCC2 complex GO:0033063 8.96 RAD51D RAD51C
3 replication fork GO:0005657 8.8 TP53 RAD51D RAD51C

Biological processes related to Peritoneum Cancer according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 WT1 TP53 PAX8 EPCAM EGFR CDKN2A
2 cellular response to DNA damage stimulus GO:0006974 9.96 TP53 RAD51D RAD51C BRCA2 BRCA1
3 negative regulation of cell proliferation GO:0008285 9.95 WT1 TP53 NF2 CDKN2A BAP1
4 positive regulation of transcription, DNA-templated GO:0045893 9.8 WT1 TP53 PAX8 EGFR CDKN2A BRCA2
5 regulation of cell cycle GO:0051726 9.73 TP53 RAD51D NF2 BAP1
6 double-strand break repair GO:0006302 9.7 TP53 BRCA2 BRCA1
7 DNA recombination GO:0006310 9.62 RAD51D RAD51C BRCA2 BRCA1
8 positive regulation of cell cycle arrest GO:0071158 9.58 TP53 CDKN2A BRCA1
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.57 TP53 EGFR
10 cellular response to gonadotropin stimulus GO:0071371 9.54 WT1 PAX8
11 chromosome organization GO:0051276 9.54 TP53 RAD51D BRCA2
12 metanephric S-shaped body morphogenesis GO:0072284 9.49 WT1 PAX8
13 metanephric epithelium development GO:0072207 9.48 WT1 PAX8
14 chordate embryonic development GO:0043009 9.46 BRCA2 BRCA1
15 double-strand break repair via homologous recombination GO:0000724 9.46 RAD51D RAD51C BRCA2 BRCA1
16 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 TP53 BRCA2 BRCA1
17 telomere maintenance via recombination GO:0000722 8.8 RAD51D RAD51C BRCA2

Molecular functions related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region sequence-specific DNA binding GO:0000976 9.46 WT1 TP53 PAX8 BRCA1
2 DNA binding GO:0003677 9.28 WT1 TP53 RAD51D RAD51C PAX8 H2AC18
3 MDM2/MDM4 family protein binding GO:0097371 8.96 TP53 CDKN2A

Sources for Peritoneum Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....